Skip to main content

Table 2 Overview of CK19+ results in volunteers, benign tumor patients and stage I–IV breast cancer patients

From: Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection

  Total number Positive Detection Rate
Healthy control 25 0/25 (0%)
Benign tumor 7 0/7 (0%)
Stage I patients 4 0/4 (0%)
Stage II patients 23 2/23 (9%)
Stage III patients 7 5/7 (70%)
Stage IV patients 7 6/7 (86%)